Impact of Homeoprophylactic Arsenicum album 30c on COVID-19 Vaccine-related Adverse Events: A Combined Retrospective–Prospective Cohort Study

Abstract

Objective Arsenicum album 30C (AA30) was recommended by the Government of India for the prevention of coronavirus infection. In the wake of the reporting of COVID-19 vaccine-related adverse events (AEs) and consequent vaccine hesitancy, this study was undertaken to assess the impact of homeo-prophylactic AA30 on COVID-19 vaccine-related AEs.

Methods This was a combined retrospective–prospective cohort study that included participants who had been enrolled in an ongoing prospective, parallel cohort study being conducted in urban slums of New Delhi and who had received either or both doses of the COVID-19 vaccine. The reporting of COVID-19 vaccine-related AEs was compared between a cohort that had been receiving homeopathic AA30 as a prophylactic for influenza-like/COVID-like illness with one in which no homeopathic intervention was provided.

Results A total of 1,737 participants who received either or both doses of vaccination for COVID-19 were included in the study, out of whom 436 participants were from the medicine cohort (MC) and 1,301 were from the control cohort (CC). Overall odds of developing AEs after either dose of COVID-19 vaccine in MC as compared with CC was found to be statistically significantly lower (overall crude OR = 0.29, 95% confidence interval [CI] = 0.23 to 0.37; p = 0.0001). The adjusted OR after accounting for age, sex, co-morbidities and vaccine type was 0.30 (95% CI = 0.24 to 0.39; p = 0.0001). The protective effect of the medicine against post-vaccination AEs was evident after the first dose as well as after the second dose, with overall crude OR being 0.37 (95% CI = 0.29 to 0.48; p = 0.0001) and 0.28 (95% CI = 0.19 to 0.41; p = 0.0001) respectively.

Conclusion Prior use of the homeopathic medicine AA30 was able to significantly reduce COVID-19 vaccine-related AEs.

Keywords

adverse event - Arsenicum album - COVID-19 - homeopathy - vaccination

Authors' Contributions

D.N. conceptualized the study. D.N., R.B., L.K., D.B., N.B., J.M., A.C., L.T., B.M., S.M., D.D., I.S., S.S., K.S.S. and A.Y. were responsible for data collection. D.N. and S.S. conducted the statistical analysis. D.N. and R.B. drafted the first version of the manuscript with relevant suggestions from co-authors. All the authors approved the version submitted for publication.

Publikationsverlauf

Eingereicht: 27. September 2024

Angenommen: 08. Januar 2025

Artikel online veröffentlicht:
12. Mai 2025

• References

• 1 Ayouni I, Maatoug J, Dhouib W. et al. Effective public health measures to mitigate the spread of COVID-19: a systematic review. BMC Public Health 2021; 21: 1015
• 2 Ho RJY. Warp-speed Covid-19 vaccine development: beneficiaries of maturation in biopharmaceutical technologies and public-private partnerships. J Pharm Sci 2021; 110: 615-618
• 3 Ball P. The lightning-fast quest for COVID vaccines – and what it means for other diseases. Nature 2021; 589: 16-18
• 4 World Health Organization. Vaccines – WHO EUL/PQ status of COVID-19 Vaccines. Accessed August 12, 2024 at: efaidnbmnnnibpcajpcglclefindmkaj/https://extranet.who.int/prequal/sites/default/files/document_files/Summary%20Status%20of%20COVID-19%20Vaccines%20within%20WHO%20EUL-PQ%20evaluation%20process%20-%2021%20May%202024_0.pdf
• 5 World Health Organization. COVID-19 vaccine tracker and landscape. Accessed August 12, 2024 at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
• 6 Ministry of Health and Family Welfare. CO-WIN Dashboard. Accessed June 13, 2024 at: https://dashboard.cowin.gov.in/
• 7 Central Drugs Standard Control Organization. COVID-19 vaccines approved for manufacture for sale or for distribution in the country. Accessed August 12, 2024 at: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTAzODE=
• 8 Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel) 2021; 9: 160
• 9 World Health Organization. Ten threats to global health in 2019. Accessed June 20, 2024 at: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
• 10 Trogen B, Oshinsky D, Caplan A. Adverse consequences of rushing a SARS-CoV-2 vaccine: implications for public trust. JAMA 2020; 323: 2460-2461
• 11 Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health 2021; 194: 245-251
• 12 de Albuquerque Veloso Machado M, Roberts B, Wong BLH, van Kessel R, Mossialos E. The relationship between the COVID-19 pandemic and vaccine hesitancy: a scoping review of literature until August 2021. Front Public Health 2021; 9: 747787
• 13 Umakanthan S, Patil S, Subramaniam N, Sharma R. COVID-19 vaccine hesitancy and resistance in india explored through a population-based longitudinal survey. Vaccines (Basel) 2021; 9: 1064
• 14 Coustasse A, Kimble C, Maxik K. COVID-19 and vaccine hesitancy. J Ambul Care Manage 2021; 44: 71-75
• 15 Callaway E. Russia's fast-track coronavirus vaccine draws outrage over safety. Nature 2020; 584: 334-335
• 16 Robbins R. Millions are skipping their second doses of Covid vaccines. The New York Times. April 25, 2021 . Accessed June 20, 2024 at: https://www.nytimes.com/2021/04/25/business/covid-vaccines-second-doses.html
• 17 Reuters. Many Indians skipping second Covid shot despite record vaccine stocks. The Times of India. October 19, 2021 . Accessed June 20, 2024 at: https://timesofindia.indiatimes.com/india/many-indians-skipping-second-covid-shot-despite-record-vaccine-stocks/articleshow/87136391.cms
• 18 The New Indian Express Bengaluru: Fear of side-effects deters people from taking second Covid jab. October 14, 2021 . Accessed June 20, 2024 at: https://www.newindianexpress.com/cities/bengaluru/2021/oct/14/fear-of-side-effects-deters-people-from-taking-second-covid-jab-2371383.html
• 19 Kaur RJ, Dutta S, Bhardwaj P. et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem 2021; 36: 427-439
• 20 Shrestha S, Khatri J, Shakya S. et al. Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. Drugs Ther Perspect 2021; 37: 376-382
• 21 Novak N, Tordesillas L, Cabanillas B. Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia. Int Rev Immunol 2022; 41: 438-447
• 22 Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci 2022; 43: 3-40
• 23 Jeet Kaur R, Dutta S, Charan J. et al. Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database. Int J Gen Med 2021; 14: 3909-3927
• 24 Buso G, Agabiti-Rosei C, Muiesan ML. The relationship between COVID-19 vaccines and increased blood pressure: a word of caution. Eur J Intern Med 2023; 111: 27-29
• 25 Pichi F, Aljneibi S, Neri P, Hay S, Dackiw C, Ghazi NG. Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi. JAMA Ophthalmol 2021; 139: 1131-1135
• 26 Leone F, Cerasuolo PG, Bosello SL. et al. Adult-onset Still's disease following COVID-19 vaccination. Lancet Rheumatol 2021; 3: e678-e680
• 27 Manzo C, Natale M, Castagna A. Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: a case report and review of literature. Aging Med (Milton) 2021; 4: 234-238
• 28 Palla P, Vergadis C, Sakellariou S, Androutsakos T. Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination: a rare adverse effect?. Hepatology 2022; 75: 489-490
• 29 Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect?. Clin Exp Vaccine Res 2021; 10: 198-201
• 30 Shinde VH. Homoeopathy in pandemic Spanish flu 1918. Indian J Res Homoeopathy 2020; 14: 152-159
• 31 Mathie RT, Baitson ES, Frye J, Nayak C, Manchanda RK, Fisher P. Homeopathic treatment of patients with influenza-like illness during the 2009 A/H1N1 influenza pandemic in India. Homeopathy 2013; 102: 187-192
• 32 Chakraborty P, Lamba CD, Nayak D. et al. Effect of individualized homoeopathic treatment in influenza like illness: a multicenter, single blind, randomized, placebo controlled study. Indian J Res Homoeopathy 2013; 7: 22-30
• 33 Hasselaar G, Nijnatten WV, Golden I. A pilot study into the comparative effectiveness and safety in the elderly of a homeopathic flu prophylaxis and the regular flu vaccination in the Netherlands. Homoeopath Links 2016; 29: 120-126
• 34 Government of India. Press Information Bureau. AYUSH: Advisory for Corona virus. Homoeopathy for Prevention of Corona virus Infections. Unani Medicines useful in symptomatic management of Corona Virus infection. January 29, 2020 . Accessed June 20, 2024 at: https://pib.gov.in/PressReleasePage.aspx?PRID=1600895
• 35 Varanasi R, Nayak D, Khurana A. Clinical repurposing of medicines is intrinsic to homeopathy: research initiatives on COVID-19 in India. Homeopathy 2021; 110: 198-205
• 36 Manchanda RK, Miglani A, Gupta M. et al. Homeopathic remedies in COVID-19: prognostic factor research. Homeopathy 2021; 110: 160-167
• 37 Ministry of Health & Family Welfare. Homoeopathic Pharmacopoeia of India. New Delhi:: Government of India; 1971. : vol. 1: 283
• 38 Dutta S, Kaur RJ, Bhardwaj P. et al. Adverse events reported from the COVID-19 vaccines: a descriptive study based on the WHO database (VigiBase®). J Appl Pharm Sci 2021; 11: 1-9
• 39 Xiong X, Yuan J, Li M, Jiang B, Lu ZK. Age and gender disparities in adverse events following COVID-19 vaccination: real-world evidence based on big data for risk management. Front Med (Lausanne) 2021; 8: 700014
• 40 Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ 2021; 372: n149
• 41 Khan F, Khan MT, Zaman S. et al. Side effects of COVID-19 vaccines among diabetic subjects and healthy individuals. Cureus 2023; 15: e36005
• 42 Simonini M, Scarale MG, Tunesi F. et al. COVID-19 vaccines effect on blood pressure. Eur J Intern Med 2022; 105: 109-110
• 43 Angeli F, Reboldi G, Trapasso M, Santilli G, Zappa M, Verdecchia P. Blood pressure increase following COVID-19 vaccination: a systematic overview and meta-analysis. J Cardiovasc Dev Dis 2022; 9: 150
• 44 Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother 2016; 12: 2391-2402
• 45 Etminan M, Sodhi M, Ganjizadeh-Zavareh S. Should antipyretics be used to relieve acute adverse events related to COVID-19 vaccines?. Chest 2021; 159: 2171-2172
• 46 Ooi EE, Dhar A, Petruschke R, Locht C, Buchy P, Low JGH. Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. NPJ Vaccines 2022; 7: 31
• 47 Nayak D, Nahar K, Bhalerao R. et al. Effectiveness of Arsenicum album 30C in prevention of COVID-19 in individuals residing in containment zones of Delhi – a prospective, community-based, parallel cohort study. Homeopathy 2022; 111: 261-270
• 48 Dhighe L, Prajapati P, Patel N, Kukadiya J. Clinical trial of homoeopathic genus epidemicus ‘Arsenic alba’ as a prophylactic during pandemic of Covid 19 in India at Dr V H Dave Homoeopathic Medical College. Natl J Integr Res Med 2021; 12: 62-65
• 49 Vizcarra P, Haemmerle J, Velasco H. et al. BNT162b2 mRNA COVID-19 vaccine reactogenicity: the key role of immunity. Vaccine 2021; 39: 7367-7374
• 50 Xu K, Dai L, Gao GF. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. Int Immunol 2021; 33: 529-540
• 51 Agustin M, Trifitriana M, Danarti R. COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review. BMC Infect Dis 2023; 23: 7
• 52 Van Wassenhoven M. Clinical verification in homeopathy and allergic conditions. Homeopathy 2013; 102: 54-58
• 53 Aphale P, Sanap A, Sharma D. et al. Stem cell secretome modulated by Arsenicum album 30C ameliorates lipopolysaccharide-induced cytokine storm in blood mononuclear cells in vitro . Homeopathy 2024; 113: 132-141
• 54 Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383: 2255-2273
• 55 Mathioudakis AG, Ghrew M, Ustianowski A. et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life (Basel) 2021; 11: 249